AN EXPLORATORY SINGLE ARM STUDY ON THE EFFICACY OF MOORVADI AGAD IN GARAVISHA JANYA DHATWAGNIMANDYA (HYPOTHYROIDISM) – A REVIEW ARTICLE

Background: Hypothyroidism is a common endocrine disorder characterized by reduced metabolic activity due to deficient thyroid hormone production. Despite the availability of hormone replacement therapy, many patients continue to experience symptoms and adverse effects. Ayurveda conceptualizes hypothyroidism as Garavisha Janya Dhatwagnimandya, where chronic exposure to incompatible diet, food additives, preservatives, and environmental toxins impairs Agni (digestive and metabolic fire), leading to Ama formation, Srotorodha (channel obstruction), and diminished tissue metabolism. Moorvadi Agad, described in Ashtanga Sangraha for Garavisha, possesses Vishaghna, Deepana, Pachana, and Srotoshodhana properties. This study evaluated its efficacy in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism). Methods: A prospective, interventional, single-arm clinical trial was conducted on 30 patients aged 1860 years with primary hypothyroidism (TSH >5.4 µIU/mL and <15 µIU/mL) and a history of Garavisha exposure. Participants received Moorvadi Agad Churna 3 g orally thrice daily before meals with lukewarm water for 60 days. Assessment included subjective symptom scoring (general weakness, tiredness, hair loss, constipation, dyspnoea, hoarseness, menstrual abnormality, dry skin, cold intolerance, swelling, bradycardia) and objective parameters (TSH, T3, T4, BMI, body weight) at baseline and post-treatment. Data were analyzed using the Wilcoxon signed-rank test and paired t-test. Results: The mean TSH level decreased significantly from 12.37±8.66 mIU/L to 5.64±5.49 mIU/L (54.42% reduction, p<0.001). Overall subjective symptom score improved by 82.8% (p<0.001), with excellent relief in hoarseness (90.4%), constipation (90.1%), menstrual abnormalities (89.2%), hair loss (84.7%), dry skin (83.4%), swelling (83.3%), cold intolerance (82.8%), dyspnoea (80.8%), tiredness (80.0%), and general weakness (78.7%). BMI decreased from 24.29±2.49 to 23.35±2.24 (3.87% reduction, p<0.0001), and body weight reduced from 68.90±10.64 kg to 65.93±10.06 kg (4.31% reduction, p<0.0001). No adverse drug reactions were reported. Conclusion: Moorvadi Agad demonstrated significant efficacy and safety in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism), offering a holistic approach addressing the underlying metabolic dysfunction and toxic burden.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-14
DOI
https://doi.org/10.25258/ijddt.16.90s.101
Primary Topic
Traditional Chinese Medicine Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AN EXPLORATORY SINGLE ARM STUDY ON THE EFFICACY OF MOORVADI AGAD IN GARAVISHA JANYA DHATWAGNIMANDYA (HYPOTHYROIDISM) – A REVIEW ARTICLE

Dr.Neelanjana Sen, Ritu Kapoor
International Journal of Drug Delivery Technology
Traditional Chinese Medicine Studies
article

AN EXPLORATORY SINGLE ARM STUDY ON THE EFFICACY OF MOORVADI AGAD IN GARAVISHA JANYA DHATWAGNIMANDYA (HYPOTHYROIDISM) – A REVIEW ARTICLE

Dr.Neelanjana Sen, Ritu Kapoor
article en

Abstract

Background: Hypothyroidism is a common endocrine disorder characterized by reduced metabolic activity due to deficient thyroid hormone production. Despite the availability of hormone replacement therapy, many patients continue to experience symptoms and adverse effects. Ayurveda conceptualizes hypothyroidism as Garavisha Janya Dhatwagnimandya, where chronic exposure to incompatible diet, food additives, preservatives, and environmental toxins impairs Agni (digestive and metabolic fire), leading to Ama formation, Srotorodha (channel obstruction), and diminished tissue metabolism. Moorvadi Agad, described in Ashtanga Sangraha for Garavisha, possesses Vishaghna, Deepana, Pachana, and Srotoshodhana properties. This study evaluated its efficacy in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism). Methods: A prospective, interventional, single-arm clinical trial was conducted on 30 patients aged 1860 years with primary hypothyroidism (TSH >5.4 µIU/mL and <15 µIU/mL) and a history of Garavisha exposure. Participants received Moorvadi Agad Churna 3 g orally thrice daily before meals with lukewarm water for 60 days. Assessment included subjective symptom scoring (general weakness, tiredness, hair loss, constipation, dyspnoea, hoarseness, menstrual abnormality, dry skin, cold intolerance, swelling, bradycardia) and objective parameters (TSH, T3, T4, BMI, body weight) at baseline and post-treatment. Data were analyzed using the Wilcoxon signed-rank test and paired t-test. Results: The mean TSH level decreased significantly from 12.37±8.66 mIU/L to 5.64±5.49 mIU/L (54.42% reduction, p<0.001). Overall subjective symptom score improved by 82.8% (p<0.001), with excellent relief in hoarseness (90.4%), constipation (90.1%), menstrual abnormalities (89.2%), hair loss (84.7%), dry skin (83.4%), swelling (83.3%), cold intolerance (82.8%), dyspnoea (80.8%), tiredness (80.0%), and general weakness (78.7%). BMI decreased from 24.29±2.49 to 23.35±2.24 (3.87% reduction, p<0.0001), and body weight reduced from 68.90±10.64 kg to 65.93±10.06 kg (4.31% reduction, p<0.0001). No adverse drug reactions were reported. Conclusion: Moorvadi Agad demonstrated significant efficacy and safety in managing Garavisha Janya Dhatwagnimandya (Hypothyroidism), offering a holistic approach addressing the underlying metabolic dysfunction and toxic burden.

International Journal of Drug Delivery TechnologyVol. 16(90s)
National Institute of Ayurveda (IN)
Traditional Chinese Medicine Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon